Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2008-09-18

FDA Approved: UROXATRAL — Supplemental Application (Advanz Pharma (US) Corp.)

View source ↗

Summary

The FDA approved a supplemental application for UROXATRAL (alfuzosin hydrochloride) from Advanz Pharma (US) Corp., updating the existing NDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Uroxatral (Alfuzosin)

Snippet

SUPPL AP for UROXATRAL (ALFUZOSIN HCL)